Drug Profile
Chlamydia trachomatis vaccine - Emergent BioDefense Operations Lansing
Alternative Names: TracVaxLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Emergent BioDefense Operations Lansing
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chlamydial infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Chlamydial-infections in USA (Parenteral, Injection)
- 07 Mar 2006 This vaccine is still in active development
- 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation